EFTA01092032Set 9
25p12,760w
Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question?
It's pre-clinical, manufacturing,
and clinical data that drive safety.
Companies mentioned include:
Athersys, Inc. (ATHX) - $1.68 - Buy
Baxter ... qualify as manipulated products; therefore,
the safety of both products must be assessed in pre-clinical,
manufacturing, and clinical studies. We believe both allogeneic
and autologous products will be approved ... control of the manufacturing steps and release criteria are needed as early as
the pre-clinical stage to demonstrate the safety of the cells. The only process that
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf
EFTA00964821Set 9
2013-07-084p548w
Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question?
It's pre-clinical, manufacturing, and clinical data that drive safety
Date ... Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question? It's pre-clinical,
manufacturing, and clinical data that drive safety
Steven Victor MD
Chairman
Intellicell Biosciences ... Maxim Group: Regenerative Cell Therapy: Autologous versus allogeneic is the wrong question? It's pre-clinical,
manufacturing, and clinical data that drive safety
Steven Victor MD
Chairman
Intellicell Biosciences
https://www.justice.gov/epstein/files/DataSet%209/EFTA00964821.pdf
EFTA01092527Set 9
2012-07-163p899w
group of early investors, directors,
founders, and advisers who have helped facilitate the validating pre-clinical
proof-of-concept data that Dr. Lee Arnold, our Chief Scientific Officer
https://www.justice.gov/epstein/files/DataSet%209/EFTA01092527.pdf